Sabinsa Secures Approval From Government of India to Use Its Ocufors(TM) Eye Drop Solution for Glaucoma Treatment

Sabinsa Secures Approval From Government of India to Use Its Ocufors(TM) Eye Drop Solution for Glaucoma Treatment Company has been granted permission by the Drugs Controller General of India to manufacture and market Ocufors(TM), an ophthalmic solution containing one percent forskolin, for the treatment of glaucoma.
Home Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P. Natrol Appoints Vincent Andrich VP Sales for Prolab Division Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results Body Shop Reports 24.8 Mil Euro Sales Revenues Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label Supplement Group Targets Consumer Education Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO drugstore.com Expects to Reach Profitability Target in 2003 Human Genome Project Leads to Innovative Healthcare NPIcenter’s Career Center targets nutraceutical Industry Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Editorial: An Exercise in Synergy NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway Natural Health Trends Corp. Launches Lexxus Taiwan FDA Presents Compliance Guide for Structure/Function Claims New TrimFit® Bars Redefine Energy Bar Category New TrimFit® Bars Redefine Energy Bar Category Probiata® Offers Safe, Natural and Effective Alternative Alive & Well with Michelle Harris Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com Consumers Search for Healthy Cleaning Products That Work Nordic Naturals: Omega 3 Fatty Acids Cyanotech Names Bob Capelli as Director of Sales Appeals Court Rules for FDA in Ephedra Ban: Overturns Lower Court Finding in Nutraceutical v. von Eschenbach A three-judge panel of the 10th Circuit U.S. Court of Appeals ruled yesterday in favor of the U.S. Food and Drug Administration (FDA) in a case that had challenged the agency's 2004 prohibition of any level of ephedrine in dietary supplements. "The evidence in the administrative record was sufficiently probative to demonstrate by a preponderance of the evidence that EDS [ephedrine dietary supplements] at any dose level pose an unreasonable risk. The greater weight of the evidence supports the FDA’s ban on EDS, thus satisfying the agency's burden." Appeals Court Rules for FDA in Ephedra Ban: Overturns Lower Court Finding in Nutraceutical v. von Eschenbach A three-judge panel of the 10th Circuit U.S. Court of Appeals ruled yesterday in favor of the U.S. Food and Drug Administration (FDA) in a case that had challenged the agency's 2004 prohibition of any level of ephedrine in dietary supplements. "The evidence in the administrative record was sufficiently probative to demonstrate by a preponderance of the evidence that EDS [ephedrine dietary supplements] at any dose level pose an unreasonable risk. The greater weight of the evidence supports the FDA’s ban on EDS, thus satisfying the agency's burden." Appeals Court Rules for FDA in Ephedra Ban: Overturns Lower Court Finding in Nutraceutical v. von Eschenbach A three-judge panel of the 10th Circuit U.S. Court of Appeals ruled yesterday in favor of the U.S. Food and Drug Administration (FDA) in a case that had challenged the agency's 2004 prohibition of any level of ephedrine in dietary supplements. "The evidence in the administrative record was sufficiently probative to demonstrate by a preponderance of the evidence that EDS [ephedrine dietary supplements] at any dose level pose an unreasonable risk. The greater weight of the evidence supports the FDA’s ban on EDS, thus satisfying the agency's burden." FDA Statement on Tenth Circuit’s Ruling to Uphold FDA Decision Banning Dietary Supplements Containing Ephedrine Alkaloids FDA states that no dosage of dietary supplements containing ephedrine alkaloids is safe and the sale of these products in the United States is illegal and subject to FDA enforcement action. FDA Statement on Tenth Circuit’s Ruling to Uphold FDA Decision Banning Dietary Supplements Containing Ephedrine Alkaloids FDA states that no dosage of dietary supplements containing ephedrine alkaloids is safe and the sale of these products in the United States is illegal and subject to FDA enforcement action. FDA Statement on Tenth Circuit’s Ruling to Uphold FDA Decision Banning Dietary Supplements Containing Ephedrine Alkaloids FDA states that no dosage of dietary supplements containing ephedrine alkaloids is safe and the sale of these products in the United States is illegal and subject to FDA enforcement action. FDA Statement on Tenth Circuit’s Ruling to Uphold FDA Decision Banning Dietary Supplements Containing Ephedrine Alkaloids FDA states that no dosage of dietary supplements containing ephedrine alkaloids is safe and the sale of these products in the United States is illegal and subject to FDA enforcement action. Government of Canada Awards Site License to Sangster’s Health Centres Sangster’s Health Centres, (a member of Planet Organic Health Corp. POH-TSX Venture Exchange), announces that Darwen Holdings, the product distribution division of Sangster’s Health Centres has been awarded a site license under The Government of Canada’s Natural Health Products Regulations (NHP). Government of Canada Awards Site License to Sangster’s Health Centres Sangster’s Health Centres, (a member of Planet Organic Health Corp. POH-TSX Venture Exchange), announces that Darwen Holdings, the product distribution division of Sangster’s Health Centres has been awarded a site license under The Government of Canada’s Natural Health Products Regulations (NHP). Government of Canada Awards Site License to Sangster’s Health Centres Sangster’s Health Centres, (a member of Planet Organic Health Corp. POH-TSX Venture Exchange), announces that Darwen Holdings, the product distribution division of Sangster’s Health Centres has been awarded a site license under The Government of Canada’s Natural Health Products Regulations (NHP). AHPA Submits Comments to US Forest Service on Native Plants Proposal AHPA has submitted comments to the US Forest Service (USFS) last Friday, specifically to request that the term "native plant" be defined in language that is consistent with other federal definitions of the term, and to suggest greater clarity in a newly proposed policy statement. (May 26 USFS proposal to establish a new directive in Forest Service Manual 2070 for native plant materials.) AHPA Submits Comments to US Forest Service on Native Plants Proposal AHPA has submitted comments to the US Forest Service (USFS) last Friday, specifically to request that the term "native plant" be defined in language that is consistent with other federal definitions of the term, and to suggest greater clarity in a newly proposed policy statement. (May 26 USFS proposal to establish a new directive in Forest Service Manual 2070 for native plant materials.) Consumer Protection Deputy Director To Leave FTC C. Lee Peeler, deputy director of the Bureau of Consumer Protection for the past five years, will leave the FTC, to become president of the National Advertising Review Council and Executive Vice President for National Advertising and Self-Regulation of the Council of Better Business Bureaus. Consumer Protection Deputy Director To Leave FTC C. Lee Peeler, deputy director of the Bureau of Consumer Protection for the past five years, will leave the FTC, to become president of the National Advertising Review Council and Executive Vice President for National Advertising and Self-Regulation of the Council of Better Business Bureaus. Consumer Protection Deputy Director To Leave FTC C. Lee Peeler, deputy director of the Bureau of Consumer Protection for the past five years, will leave the FTC, to become president of the National Advertising Review Council and Executive Vice President for National Advertising and Self-Regulation of the Council of Better Business Bureaus. Consumer Protection Deputy Director To Leave FTC C. Lee Peeler, deputy director of the Bureau of Consumer Protection for the past five years, will leave the FTC, to become president of the National Advertising Review Council and Executive Vice President for National Advertising and Self-Regulation of the Council of Better Business Bureaus. Consumer Protection Deputy Director To Leave FTC C. Lee Peeler, deputy director of the Bureau of Consumer Protection for the past five years, will leave the FTC, to become president of the National Advertising Review Council and Executive Vice President for National Advertising and Self-Regulation of the Council of Better Business Bureaus. UK: Comments wanted on phytosterol French company, DRT, has asked for a decision on its phytosterol ingredient, which is derived from tall oil pitch – a substance distilled from pine resin. UK: Comments wanted on phytosterol French company, DRT, has asked for a decision on its phytosterol ingredient, which is derived from tall oil pitch – a substance distilled from pine resin. UK: Comments wanted on phytosterol French company, DRT, has asked for a decision on its phytosterol ingredient, which is derived from tall oil pitch – a substance distilled from pine resin. UK: Comments wanted on phytosterol French company, DRT, has asked for a decision on its phytosterol ingredient, which is derived from tall oil pitch – a substance distilled from pine resin. UK: Comments wanted on phytosterol French company, DRT, has asked for a decision on its phytosterol ingredient, which is derived from tall oil pitch – a substance distilled from pine resin. TGA Approves EPAX’S Omega-3 Oils For Use In Australia’s Complementary Medicine Products Company announced that after 18 months of working closely with its Australian distributor Pathway International, it has been granted regulatory approval from Australia’s Therapeutic Goods Administration (TGA), allowing EPAX’s range of omega-3 oils to be used in complementary medicine products in Australia. TGA Approves EPAX’S Omega-3 Oils For Use In Australia’s Complementary Medicine Products Company announced that after 18 months of working closely with its Australian distributor Pathway International, it has been granted regulatory approval from Australia’s Therapeutic Goods Administration (TGA), allowing EPAX’s range of omega-3 oils to be used in complementary medicine products in Australia. TGA Approves EPAX’S Omega-3 Oils For Use In Australia’s Complementary Medicine Products Company announced that after 18 months of working closely with its Australian distributor Pathway International, it has been granted regulatory approval from Australia’s Therapeutic Goods Administration (TGA), allowing EPAX’s range of omega-3 oils to be used in complementary medicine products in Australia. TGA Approves EPAX’S Omega-3 Oils For Use In Australia’s Complementary Medicine Products Company announced that after 18 months of working closely with its Australian distributor Pathway International, it has been granted regulatory approval from Australia’s Therapeutic Goods Administration (TGA), allowing EPAX’s range of omega-3 oils to be used in complementary medicine products in Australia. TGA Approves EPAX’S Omega-3 Oils For Use In Australia’s Complementary Medicine Products Company announced that after 18 months of working closely with its Australian distributor Pathway International, it has been granted regulatory approval from Australia’s Therapeutic Goods Administration (TGA), allowing EPAX’s range of omega-3 oils to be used in complementary medicine products in Australia. Cargill Expands GRAS Status of Oliggo-Fiber® Inulin and Oligofructose Products Company has expanded the GRAS (Generally Recognized As Safe) status of its Oliggo-Fiber® brand of inulin and oligofructose products through an independent evaluation by a qualified scientific expert, permitting the Oliggo-Fiber inulin and oligofructose line of products for general use in foods at levels consistent with current good manufacturing practice. Cargill Expands GRAS Status of Oliggo-Fiber® Inulin and Oligofructose Products Company has expanded the GRAS (Generally Recognized As Safe) status of its Oliggo-Fiber® brand of inulin and oligofructose products through an independent evaluation by a qualified scientific expert, permitting the Oliggo-Fiber inulin and oligofructose line of products for general use in foods at levels consistent with current good manufacturing practice. Cargill Expands GRAS Status of Oliggo-Fiber® Inulin and Oligofructose Products Company has expanded the GRAS (Generally Recognized As Safe) status of its Oliggo-Fiber® brand of inulin and oligofructose products through an independent evaluation by a qualified scientific expert, permitting the Oliggo-Fiber inulin and oligofructose line of products for general use in foods at levels consistent with current good manufacturing practice. Cargill Expands GRAS Status of Oliggo-Fiber® Inulin and Oligofructose Products Company has expanded the GRAS (Generally Recognized As Safe) status of its Oliggo-Fiber® brand of inulin and oligofructose products through an independent evaluation by a qualified scientific expert, permitting the Oliggo-Fiber inulin and oligofructose line of products for general use in foods at levels consistent with current good manufacturing practice. Hi-Fil® Lutein Achieves GRAS Status Hi-Fil® Lutein products, manufactured by Industrial Organica and distributed exclusively by Pharmline Inc., has attained self-affirmed GRAS (Generally Recognized As Safe) status, through an independent evaluation by an expert panel of scientists. Hi-Fil® Lutein Achieves GRAS Status Hi-Fil® Lutein products, manufactured by Industrial Organica and distributed exclusively by Pharmline Inc., has attained self-affirmed GRAS (Generally Recognized As Safe) status, through an independent evaluation by an expert panel of scientists. Hi-Fil® Lutein Achieves GRAS Status Hi-Fil® Lutein products, manufactured by Industrial Organica and distributed exclusively by Pharmline Inc., has attained self-affirmed GRAS (Generally Recognized As Safe) status, through an independent evaluation by an expert panel of scientists. Hi-Fil® Lutein Achieves GRAS Status Hi-Fil® Lutein products, manufactured by Industrial Organica and distributed exclusively by Pharmline Inc., has attained self-affirmed GRAS (Generally Recognized As Safe) status, through an independent evaluation by an expert panel of scientists. GRAS Status Affirmed for Lipogen Phosphatidylserine Company announces that FDA has no questions regarding the GRAS notification for its Lipogen PS (phosphatidylserine) patented product line. GRAS Status Affirmed for Lipogen Phosphatidylserine Company announces that FDA has no questions regarding the GRAS notification for its Lipogen PS (phosphatidylserine) patented product line. GRAS Status Affirmed for Lipogen Phosphatidylserine Company announces that FDA has no questions regarding the GRAS notification for its Lipogen PS (phosphatidylserine) patented product line. GRAS Status Affirmed for Lipogen Phosphatidylserine Company announces that FDA has no questions regarding the GRAS notification for its Lipogen PS (phosphatidylserine) patented product line. NSF International Awards First GMP for Sport(TM) Registration to Century Foods International NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program. NSF International Awards First GMP for Sport(TM) Registration to Century Foods International NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program. NSF International Awards First GMP for Sport(TM) Registration to Century Foods International NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program. NSF International Awards First GMP for Sport(TM) Registration to Century Foods International NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program. NSF International Awards First GMP for Sport(TM) Registration to Century Foods International NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program. NSF International Awards First GMP for Sport(TM) Registration to Century Foods International NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program. FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act. FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act. FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act. FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act. FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act. DEA: Hi-Tech Pharmaceuticals & 11 Individuals Indicted for "Generic" Pill Fraud Scheme Hi-Tech Pharmaceuticals & 11 Individuals have been indicted by a federal grand jury on multiple felony charges relating to a scheme to sell adulterated and unapproved new drugs over the internet. DEA: Hi-Tech Pharmaceuticals & 11 Individuals Indicted for "Generic" Pill Fraud Scheme Hi-Tech Pharmaceuticals & 11 Individuals have been indicted by a federal grand jury on multiple felony charges relating to a scheme to sell adulterated and unapproved new drugs over the internet. Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application. Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application. Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application. Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application. Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application. Ontario Government Closer to Regulating Traditional Chinese Medicine Ontario has moved closer to regulating traditional Chinese medicine (TCM) and acupuncture as the proposed legislation moved to second reading. Ontario Government Closer to Regulating Traditional Chinese Medicine Ontario has moved closer to regulating traditional Chinese medicine (TCM) and acupuncture as the proposed legislation moved to second reading. Ontario Government Closer to Regulating Traditional Chinese Medicine Ontario has moved closer to regulating traditional Chinese medicine (TCM) and acupuncture as the proposed legislation moved to second reading. FDA Authorizes Qualified Health Claim for Canola Oil The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states: Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil. FDA Authorizes Qualified Health Claim for Canola Oil The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states: Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil. FDA Authorizes Qualified Health Claim for Canola Oil The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states: Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil. FDA Authorizes Qualified Health Claim for Canola Oil The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states: Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil. FDA Authorizes Qualified Health Claim for Canola Oil The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states: Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil. FDA Authorizes Qualified Health Claim for Canola Oil The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states: Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil. Allimax Nutraceuticals US starts clinical trial for treating Lyme disease Allimax Nutraceuticals US, in conjunction with the Health Healing and Hope Foundation, have started their Lyme disease double blind clinical study being conducted in Texas by Dr.’s Joan Vandergriff ND, Hamid Moayad DO, William Keller Ph.D., Hugo Rodier M.D. Allimax Nutraceuticals US starts clinical trial for treating Lyme disease Allimax Nutraceuticals US, in conjunction with the Health Healing and Hope Foundation, have started their Lyme disease double blind clinical study being conducted in Texas by Dr.’s Joan Vandergriff ND, Hamid Moayad DO, William Keller Ph.D., Hugo Rodier M.D. Health Canada Issues 'Approach to the Refusal of Product license Applications' Health Canada has issued a notice regarding its approach to the refusal of Product License Applications. The approach is posted at http://www.hc-sc.gc.ca/dhp-mps/prodnatur/bulletins/pl-ref-lp_e.html. Health Canada Issues 'Approach to the Refusal of Product license Applications' Health Canada has issued a notice regarding its approach to the refusal of Product License Applications. The approach is posted at http://www.hc-sc.gc.ca/dhp-mps/prodnatur/bulletins/pl-ref-lp_e.html. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Synergy Flavors Invests in Sensory Flavor Profiling Research Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders. NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Heart Health Alert: Niacin May Reverse Hardening of the Arteries Spotlight on Savory Side Dishes Spotlight on Savory Side Dishes Spotlight on Savory Side Dishes Another Reason to Choose Healthy Lifestyle Habits Another Reason to Choose Healthy Lifestyle Habits	PISCATAWAY, N.J., Sept 05, 2006 /PRNewswire via COMTEX/ -- Sabinsa Corporation, a manufacturer and supplier of high quality herbal extracts, cosmeceuticals, minerals and specialty fine chemicals, has been granted permission by the Drugs Controller General of India to manufacture and market Ocufors(TM), an ophthalmic solution containing one percent forskolin, for the treatment of glaucoma. This is the first time that the government of India has approved a product developed from natural sources for use as a pharmaceutical grade drug. "Research and development has always been strength and focus for Sabinsa, and through our ongoing efforts we were able to develop this stable, water- soluble forskolin solution that has been shown in clinical trials to be 30 percent more effective than the most popular glaucoma treatment on the world market today," noted Dr. Muhammed Majeed, founder and CEO, Sabinsa Corporation. "It is an honor to receive this approval, which speaks highly about our stringent safety, efficacy and quality standards, which we apply to all of our ingredients whether they be prescription grade, generic commodities or our branded offerings." Glaucoma is a degenerative disease of the optic nerve, often caused by increased pressure inside the eye. Glaucoma affects more than 50 million individuals worldwide and is the second leading cause of blindness across the globe. Ocufors, which is administered as an eye drop, offers an effective treatment for glaucoma with few to no side effects because it is a natural product. Sabinsa is currently seeking registration for Ocufors in the U.S., Europe and Australia. Sabinsa currently holds U.S. Patent #6,960,300 surrounding the process for preparing Ocufors, as well as its application. The invention describes methods to prepare clear solutions of diterpenes, such as forskolin and its congeners that are sparingly soluble or insoluble in water, for convenient use in ophthalmic preparations as well as in topical, oral, injectable and other dosage forms, for human and veterinary use. The active ingredient in Ocufors, forskolin, is derived from the herb Coleus forskohlii, a plant native to subtropical and warm temperate habitats, and a member of the mint family. Coleus forskohlii is the only known plant source of forskolin, which has traditionally been used to increase lean body mass and optimize body composition. Sabinsa holds U.S. Patent #5,804,596 and European Patent # EP0977564 for the use of forskolin as a weight management ingredient and currently the company has approximately 10,000 acres dedicated to the cultivation of Coleus forskohlii across various regions in India. Sabinsa Corporation, founded in 1988, is a manufacturer and supplier of herbal extracts, cosmeceuticals, minerals and specialty fine chemicals. Sabinsa's mission is to provide alternative and complementary natural products for human nutrition and well-being. Over the past nine years, Sabinsa has brought to market more than 30 standardized botanical extracts and privately funded several clinical studies in conjunction with prestigious institutions in support of these products. With more than 100 scientists working full time conducting ongoing research both in India and the United States, Sabinsa continues to develop and patent phytonutrients for the world market. All products intended for human consumption are certified Kosher. For more information visit www.sabinsa.com.
Powered By Traffic Booster Absolute News Manager Plug-in by Xigla Software